Abstract
Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients.
Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1).
Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group).
Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.
Keywords: Alternative therapy, Epilepsy, Long-term study, Neurosurgery, Pharmacoresistance, Vagus nerve stimulation, Neurological Disorder, Antilepitic Drugs, Antilepitic effect, Rationale, Dosing, Epileptic Patient, Aetiologies, Epileptic Seizures, Lennox Gastaut syndrome lepsy
Letters in Drug Design & Discovery
Title: Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center
Volume: 8 Issue: 4
Author(s): Chiara Pizzanelli, Renato Galli, Filippo S. Giorgi, Alfonso Iudice, Enrica Bonanni, Veronica Pelliccia, Stella Jensen, Laura Manca, Bruno Lenzi, Ludovico Lutzemberger, Giuliano Parenti, Francesco Fornai and Luigi Murri
Affiliation:
Keywords: Alternative therapy, Epilepsy, Long-term study, Neurosurgery, Pharmacoresistance, Vagus nerve stimulation, Neurological Disorder, Antilepitic Drugs, Antilepitic effect, Rationale, Dosing, Epileptic Patient, Aetiologies, Epileptic Seizures, Lennox Gastaut syndrome lepsy
Abstract: Purpose: Vagus Nerve Stimulation (VNS) is indicated in the treatment of pharmacoresistant epilepsy. Albeit its general efficacy, the use of VNS remains undefined concerning two points: i) there are only a few long-term studies, none randomized; ii) there are no clinical markers which allow to predict VNS response. In order to explore these points, we report the long-term outcomes of VNS in 22 patients.
Methods: Twenty-two patients with refractory epilepsy, either symptomatic generalized or cryptogenic/symptomatic partial were treated with VNS and monitored up to 15 years (6.5±1.1).
Results: No significant adverse events were observed. VNS efficacy was enduring and increased significantly over time. Seizure frequency decreased by 34.3±3.9% after 1 year, 40.3±4.6% after 2 years, 48.0±5.4% after 3 years, 53.4±7.9% after 5 years and 48.1%±5.8 at maximum follow up. Data on syndrome-specificity were not significant (small number of patients in each group).
Conclusions: This study confirms sustained efficacy of VNS in epilepsy. Generalized symptomatic and temporal lobe epilepsy seem to be associated to a better outcome to VNS, but additional data are required.
Export Options
About this article
Cite this article as:
Pizzanelli Chiara, Galli Renato, S. Giorgi Filippo, Iudice Alfonso, Bonanni Enrica, Pelliccia Veronica, Jensen Stella, Manca Laura, Lenzi Bruno, Lutzemberger Ludovico, Parenti Giuliano, Fornai Francesco and Murri Luigi, Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center, Letters in Drug Design & Discovery 2011; 8 (4) . https://dx.doi.org/10.2174/157018011794839394
DOI https://dx.doi.org/10.2174/157018011794839394 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Seeing Early Signs of Alzheimer's Disease Through the Lens of the Eye
Current Alzheimer Research Impact of Novel Screening Technologies on Ion Channel Drug Discovery
Combinatorial Chemistry & High Throughput Screening The Putative Neuroprotective Role of Neuropeptide Y in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Toward the Identification of Novel Carbonic Anhydrase XIV Inhibitors using 3D-QSAR Pharmacophore Model, Virtual Screening and Molecular Docking Study
Letters in Drug Design & Discovery Medical Technology: A Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management
Current Neuropharmacology Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Sexual Dysfunction in Epilepsy and the Role of Anti-Epileptic Drugs
Current Pharmaceutical Design Molecular Structure of Ionotropic Glutamate Receptors
Current Medicinal Chemistry Neurotransmitter Effects in Human Immunodeficiency Virus (HIV) and Simian Immuno-Deficiency Virus (SIV) Infection
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Small Molecule-induced Beta-cell Regeneration from Alternate Cell Sources
Current Tissue Engineering (Discontinued) Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry